Is Trabectedin officially on the market?

Trabectedin (Trabectedin), as an anti-cancer drug with a unique source and novel mechanism of action, has been officially approved for marketing overseas. As early as 2007, the European Medicines Agency (EMA) approved it for the treatment of patients with inoperable or recurrent soft tissue sarcoma. Subsequently, the US FDA also approved its marketing in 2015 for the treatment of specific types of advanced soft tissue sarcoma. It can be seen that trabectedin has entered the stage of routine clinical use in countries and regions such as Europe and the United States, indicating that its efficacy and safety have been recognized by authoritative institutions.

However, in mainland China, trabectedin has not yet been approved by the National Food and Drug Administration (NMPA), nor has it been included in the medical insurance reimbursement list. This means that patients cannot obtain the drug through direct prescription from regular domestic hospitals. For patients with clinical needs who want to use trabectedin, they usually need to use overseas channels. At this stage, some formal and compliant international medical institutions or cross-border pharmacies can help patients obtain the EU version or the original Hong Kong version of trabectedin. Such channels provide patients with medication accessibility on the premise of legal compliance.

It is worth noting that the pricing of trabectedin falls into the category of expensive drugs overseas. Due to high research and development costs and narrow indications, its price is significantly higher than conventional chemotherapy drugs. Because of this, it is not yet covered by China’s health insurance system. When patients choose to purchase through overseas channels, in addition to paying attention to the regularity of the source of the medicine, they also need to fully understand the possible side effects and treatment risks of the medicine and avoid self-medication.

Globally, the marketing of trabectedin demonstrates its establishment as an important treatment option in specific tumor types. Particularly in rare cancers such as soft tissue sarcoma and ovarian cancer, trabectedin offers the opportunity to continue treatment after resistance to other drugs.

Reference materials:https://www.drugs.com/monograph/trabectedin.html